Back to search

Article

Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort study

2023-10-17

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold> According to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, both immunohistochemical HER2(3+) and HER2(2+)/in situ hybridization (ISH) amplified [HER2(2+)/ISH+] breast cancer(BC)s fall under the HER2-positive BC category.However,there is a lack of studies exploring the difference of neoadjuvant therapeutic response...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
db3ed245-a1ed-54c4-9e3a-2a2210d7e10d
DOI
10.21203/rs.3.rs-3414063/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comparison of the response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH-positive early- stage breast cancer: A retrospective multicenter cohort studyDOI 10.21203/rs.3.rs-3414063/v1
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancerSemantic proximity
Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional AnalysisSemantic proximity
Clinicopathological features and prognosis of HER2 low-expression breast cancer: a single-center retrospective studySemantic proximity
Neoadjuvant Chemotherapy in early-stage breast cancer: the trend over time and the impact on axillary management, A National Cancer Database AnalysisSemantic proximity
Clinical Validation of RlapsRisk BC in an international multi-cohorts settingSemantic proximity
HER3 Expression and PIK3CA Mutational Status Predict Pathological Response of Neoadjuvant Therapy in HER2-Positive Breast Cancer Patients.Semantic proximity
Gene expression before and after neoadjuvant chemotherapy or endocrine therapy and survival outcomes in hormone receptor-positive, HER2-negative breast cancer: the NEOENDO studySemantic proximity
Molecular intrinsic subtypes, genomic and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity
Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - one clinic experience.Semantic proximity
Novel Prognostic Stratification and Therapeutic Implications in T1N0M0 Breast Cancer: Insights from a Multi-Center Chinese CohortSemantic proximity
Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity
Select a neighboring publication to make it the new centre.